| BCBS Oklahoma Medical Policies | Natalizumab and Associated Biosimilar(s) | 2025-11-01 |
| BCBS Oklahoma Medical Policies | Nonwearable Automatic External Defibrillators | 2025-11-01 |
| BCBS Oklahoma Medical Policies | Remdesivir | 2025-11-01 |
| BCBS Oklahoma Medical Policies | Secukinumab | 2025-11-01 |
| BCBS Oklahoma Medical Policies | Teprotumumab-trbw | 2025-11-01 |
| BCBS Oklahoma Medical Policies | Thermography | 2025-11-01 |
| BCBS Oklahoma Medical Policies | Use of a Medial Knee Implantable Shock Absorber | 2025-11-01 |
| BCBS New Mexico Medical Policies | Abatacept | 2025-11-01 |
| BCBS New Mexico Medical Policies | Bioengineered Skin and Soft Tissue Substitutes | 2025-11-01 |
| BCBS New Mexico Medical Policies | Biomarker Testing in Risk Assessment and Management of | 2025-11-01 |